Harpoon Therapeutics Inc
Change company Symbol lookup
Select an option...
HARP Harpoon Therapeutics Inc
VIRC Virco Mfg Corp
RVLP RVL Pharmaceuticals PLC
TRGP Targa Resources Corp
RCRT Recruiter.Com Group Inc
VGAS Verde Clean Fuels Inc
DHHC DiamondHead Holdings Corp
EJH E-Home Household Service Holdings Ltd
FLGC Flora Growth Corp
HL Hecla Mining Co

Health Care : Biotechnology | Small Cap Value
Company profile

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in the developing a T cell engager that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. It is developing a pipeline of T cell engagers using its TriTACs, focused on the treatment of solid tumors and hematologic malignancies. It has also nominated its clinical candidate using its ProTriTAC platform, a prodrug version of its TriTAC platform, designed to expand the target space for T cell engagers and bring the benefits of TriTACs to the patients. The Company’s TriTAC product candidates include HPN328, HPN217 and HPN536. The Company’s ProTriTAC product candidate include HPN601. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells.

Closing Price
Day's Change
-0.0145 (-2.11%)
B/A Size
Day's High
Day's Low

10-day average volume:

Raytheon's profit more than doubles as Ukraine war boosts defense budgets

7:58 am ET January 25, 2023 (MarketWatch)

By Ciara Linnane

Company to streamline into three operating segments and merge missiles and intelligence systems

Shares of Raytheon Technologies Corp., the maker of the Stinger and Javelin missiles, rose Tuesday, after the company posted fourth-quarter profit that more than doubled from the year-earlier period, offsetting a slight miss on sales.

Chief Executive Greg Hayes said the Russian invasion of Ukraine had boosted demand for its products as governments raise defense budgets. The U.S. government said in December it would offer Raytheon's Patriot air and missile defense system to Ukraine to help it defend itself against Russian missiles.

"We remain in lockstep with the U.S. government to ensure we can continue to support our allies," Hayes told analysts on the company's earnings call.

See now:In reversal, U.S. poised to approve Abrams tanks for Ukraine

Related: Russia-Ukraine war leaves Doomsday Clock closest to 'crisis' hour of midnight in report's 76-year history

The European Union is planning to increase military spending by 70 billion euros ($76.1 billion) in the next three years, while Japan is aiming to boost its spending by 26%, said Christopher Calio, newly appointed chief operating officer, on the call.

In its aerospace segment, Raytheon (RTX) is benefiting from the recovery in travel, that has seen demand climb at a time when airlines are facing supply chain issues and flying planes for longer, boosting demand for parts and aftermarket services.

The company's Collins Aerospace segment saw sales climb 15% to $5.662 billion in the period. Engine maker Pratt & Whitney saw sales rise 10% to $5.652 billion.

"In commercial aerospace, we expect global air traffic to fully recover to 2019 levels as we exit 2023 with continued strength in the U.S. and Europe," said Calio. "This is pretty consistent from what we're all hearing from the airlines."

The company is expecting the lifting of COVID restrictions in China to boost traffic levels, with China representing about 14% of global air traffic, he said.

"We're also seeing traffic in other parts of the world remain resilient," said Calio. Raytheon is now expecting commercial aftermarket revenue growth across its aerospace businesses to approach 20% in 2023 and for commercial production rates to climb around 20%.

Still, Raytheon executives acknowledged that inflation, supply chain snags and labor shortages are likely to remain headwinds this year.

"While we are broadly beginning to see our supply chain improve, it's not yet at the levels we need. We are assuming a recovery as we move into the back half of the year," said Calio.

The company is planning to streamline into three segments; Collins Aerospace, Pratt & Whitney and Raytheon. The move will merge the former Raytheon Intelligence & Space and Raytheon Missiles & Defense segments. It expects to complete the realignment in the second half of 2023.

Robert Stallard, global aerospace and defense analyst at Vertical Research Partners, said the numbers confirmed current trends.

"Given that Raytheon has exposure to pretty much every market in aerospace & defense, its outlook neatly encapsulates the broad themes that we expect to play out this year," Stallard wrote in a note to clients.

"Very basically, demand continues to exceed supply in defense and aerospace OEM [original equipment manufacturing], while the aero aftermarket continues to enjoy its 'sweet spot'. Raytheon management expects the supply chain issues to ease in the second half, with further progress into 2024--and that is probably the biggest risk to the numbers this year (as it was in 2022)."

Stallard reiterated his buy rating on the stock and $109 price target, that is about 11% above its current price.

See now: Expedia, Airbnb stocks surge after analysts say online-travel demand is still strong

Overall, Raytheon had net income of $1.422 billion, or 96 cents a share, in the quarter, more than double the $686 million, or 46 cents a share, posted in the year-earlier period. Adjusted per-share earnings came to $1.27, ahead of the $1.24 FactSet consensus.

Sales rose to $18.093 billion from $17.044 billion a year ago, below the $18.200 billion FactSet consensus. The company ended the quarter with a backlog of $175 billion. T

For the full year, it now expects sales of $72.0 billion to $73.0 billion, compared with a FactSet consensus of $72.3 billion. It expects adjusted EPS of $4.90 to $5.05, compared with a FactSet consensus of $5.03.

The stock has gained 12% in the last 12 months, while the S&P 500 has fallen 9%.

-Ciara Linnane


(END) Dow Jones Newswires

January 25, 2023 07:58 ET (12:58 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.